One of the most interesting new drugs now being introduced in the therapy of allergic reactions, in particular asthma, is ketotifen, which shows clearly distinguishable anti-anaphylactic and antihistaminic effects. In animal experiments it inhibits passive cutaneous anaphylaxis and experimental asthma in rats as well as the 48/80 induced his-tamine release from peritoneal mast cells [1] . In clinical use one of its advantages is the oral administration, serum levels of 1-2 /íg/ml being achieved with only two doses of 1 mg daily. In clinical experimental trials ketotifen inhibits bronchoconstriction following challenge by histamine, acetylsalicyl-ic acid, allergens and exercise. On the other hand bronchospasm induced by acetylcho-line is not influenced [2] . Ketotifen has been shown to be at least as effective as disodium cromoglycate (DSCG) in clinical therapeutic studies, and a progressive improvement in the patients' condition has been noted during prolonged treatment. Likewise it is posExtended abstract Full paper to appear in the proceedings of the International Congress on Respiratory Diseases, Basel 1979, Prog. Resp. Res., vol. 14 (Karger, Basel 1980). sible to reduce or withdraw concurrent medication (corticosteroids and bronchodilators) [3] [4] [5] [6] . Not all patients who respond to treatment with DSCG will necessarily respond to ketotifen and vice versa. In our investigations a single dose of 2 mg ketotifen protected to the same extent as DSCG against allergen-induced bronchoconstrictions (table I). Late reactions were not influenced. As regards side-effects, DSCG can cause unpleasant local irritation apart from the problems many patients experience with the use of the spinhaler. Ketotifen mainly causes tiredness and dizziness. Although they usually decrease after a few days, patients driving a car or operating machinery should be informed. In conclusion, ketotifen is a valuable drug particularly in the treatment of allergic asthma but also in exercise induced and some cases of intrinsic asthma. No final statement can be made about long-term treatment although the results available are very positive. Future investigations should also be directed towards the best possible prediction of response in a single patient or in different categories of patients. 2 von Wichert Table I 
